EBV Antibody Testing Timing
EBV antibody testing should be performed when heterophile/Monospot tests are negative, and is most useful when obtained more than 6 weeks after symptom onset, as EBNA antibodies (which indicate infection beyond 6 weeks) take 1-2 months to develop after primary infection. 1
Initial Testing Approach
For suspected EBV mononucleosis, the diagnostic algorithm depends on timing:
Early Disease (Days 1-10)
- Heterophile antibodies become detectable between days 6-10 after symptom onset 1
- These antibodies increase through weeks 2-3 of illness
- False-negative heterophile tests occur in ~10% of patients, especially in children under 10 years 1
When Heterophile Tests Are Negative
Proceed immediately to EBV-specific antibody testing with the following panel 1:
- VCA IgM and IgG (viral capsid antigen)
- EBNA IgG (Epstein-Barr nuclear antigen)
Interpretation Based on Timing
Acute Primary Infection Pattern
- VCA IgM present (with or without VCA IgG)
- EBNA antibodies absent
- This pattern indicates recent primary infection 1
Past Infection (>6 weeks)
- EBNA antibodies present = infection occurred more than 6 weeks prior
- EBNA antibodies develop 1-2 months after primary infection and persist for life 1
- Presence of EBNA makes EBV unlikely as the current cause 1
Age-Specific Considerations
In children under 6 years, especially under 3 years:
- Combine EBV antibody testing with plasma EBV-DNA PCR for optimal diagnostic accuracy 2
- EBV-DNA testing has higher diagnostic value than VCA-IgG avidity in young children 2
- Heterophile tests are particularly unreliable in this age group 1
Optimal Testing Strategy by Disease Stage
Days 0-7 after symptom onset:
- Peripheral lymphocyte count and plasma EBV-DNA testing are most useful 2
- Antibody testing may be falsely negative if performed too early
After day 7:
- VCA-IgG avidity testing becomes more reliable 2, 3
- Low avidity IgG anti-VCA indicates recent infection (within 6 months) 3
- High avidity IgG anti-VCA indicates past infection 3
Critical Pitfalls
Avoid these common errors:
- Testing too early (before day 6) may yield false-negative heterophile results
- 5-10% of EBV-infected patients never develop EBNA antibodies, so absence doesn't absolutely exclude past infection 1
- IgM can persist or give false-positives in other conditions (CMV, hepatitis, leukemia) 1
- Single time-point testing without clinical context may be misleading
Special Populations
Immunocompromised patients:
- Antibody responses may be delayed or absent
- Consider EBV viral load monitoring by PCR in peripheral blood 1
- Tissue biopsy with EBER in situ hybridization may be needed for lymphoproliferative disease 1, 4
The combination of negative EBNA IgG with low-avidity VCA IgG has 100% sensitivity and specificity for primary EBV infection 3, making this the gold standard when available.